Drugs / AMG 317
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00436670 | Mar 2007 → Sep 2008 | asthma | Amgen | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 317 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00436670 ↗ |
| Action | Inhibit | “that blocks both IL-4 and IL-13 pathways” PMID 20056900 ↗ Jan 2010 |
| Modality | Monoclonal antibody | “AMG 317 is a fully human monoclonal antibody to IL-4Ralpha” PMID 20056900 ↗ Jan 2010 |
| Route | Subcutaneous | “patients received weekly subcutaneous injections of placebo or AMG 317 (75-300 mg) for 12 weeks” PMID 20056900 ↗ Jan 2010 |
| Target | IL4R | “AMG 317 is a fully human monoclonal antibody to IL-4Ralpha” PMID 20056900 ↗ Jan 2010 |